Product Program year 2025 Source: CMS Open Payments

Ohtuvayre

Drug Pulmonary/Respiratory Diseases

Open in the dashboard

General payments

$1,751,814

32,389 payments

Research payments

$7,852,153

783 payments

Through program year 2025, $1,751,814 in general payments and $7,852,153 in research payments were reported against Ohtuvayre (Pulmonary/Respiratory Diseases).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $1,751,814 32,389
2025 Research $7,852,153 783

Breakdown

Who paid General payments · program year 2025
  1. Verona Pharma, Inc. $1,751,814 32,389 payments
Top recipients General payments · program year 2025
  1. Jonathan Kurman Pulmonary Disease · Milwaukee, WI $103,660 6% · 53 payments
  2. Keith Harris Pulmonary Disease · Port Jefferson Station, NY $102,595 6% · 89 payments
  3. Humam Farah Pulmonary Disease · Hannibal, MO $76,705 4% · 77 payments
  4. Samuel Louie Pulmonary Disease · Sacramento, CA $44,543 3% · 42 payments
  5. Sandeep Bansal Pulmonary Disease · Du Bois, PA $43,052 2% · 28 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pulmonary Disease Internal Medicine $1,097,602 66% · 2,855 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $129,377 8% · 1,857 practitioners
  3. Critical Care Medicine Internal Medicine $107,897 6% · 405 practitioners
  4. Internal Medicine $76,939 5% · 1,119 practitioners
  5. Family Medicine $52,735 3% · 1,286 practitioners

The top 5 of 90 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New York $194,366 11% · 808 recipients
  2. California $164,401 9% · 618 recipients
  3. Pennsylvania $159,225 9% · 812 recipients
  4. Wisconsin $117,692 7% · 70 recipients
  5. Missouri $92,239 5% · 298 recipients

The top 5 of 50 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

32,389 general · 783 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record